文献速递脑血管病

缺血性卒中取栓术中个体化与标准血压控制的随机临床试验

Individualized vs Standard Blood Pressure Control During Thrombectomy for Ischemic Stroke: The DETERMINE Randomized Clinical Trial.
PubMed 文献 · Neurology · 2026-08-12

DETERMINE 试验在法国8个卒中中心纳入433例前循环大血管闭塞行机械取栓的急性缺血性卒中患者,随机分为个体化血压组(术中平均动脉压维持在术前首次测量值±10%内)和对照血压组(收缩压140–180 mm Hg)。结果显示两组90天良好功能结局(mRS 0–2)比例无显著差异(44.2% vs 48.8%;aOR 0.82,95%CI 0.54–1.24;P=0.34),症状性颅内出血和90天死亡率亦无显著差异。

要点

  • 个体化血压控制未提高90天良好功能结局率。
  • 两组症状性颅内出血和90天死亡率无显著差异。
  • 术中平均血压水平和血压变异性两组无显著差异。

核心结论

  • 前循环大血管闭塞急性缺血性卒中患者取栓术中个体化血压管理未增加90天良好功能结局率。

研究设计与样本

  • 多中心、开放标签、盲法终点随机临床试验,在法国8个学术综合卒中中心进行。
  • 2021年3月10日至2023年9月18日招募,纳入433例前循环大血管闭塞且适合机械取栓的成人急性缺血性卒中患者。
  • 按1:1随机分为个体化血压组(n=215)和对照血压组(n=218),1例因撤回知情同意被排除。

主要发现

  • 90天良好功能结局(mRS 0–2)在个体化血压组为94例(44.2%),对照组为106例(48.8%);校正OR 0.82(95%CI 0.54–1.24;P=0.34)。
  • 90天全因死亡率个体化血压组18.8%,对照组16.4%;校正OR 1.19(95%CI 0.70–2.03)。
  • 两组症状性颅内出血发生率无差异。
  • 术中两组平均血压水平和血压变异性无显著差异。

关键数值与推荐

  • 个体化血压组:术中平均动脉压维持在术前首次测量值的10%以内。
  • 对照血压组:术中收缩压维持在140–180 mm Hg。
  • 主要结局:90天改良Rankin量表评分0–2分为良好功能结局。

临床怎么用

  • 取栓术中采用个体化血压管理策略未显示优于标准血压管理。
  • 标准血压管理(收缩压140–180 mm Hg)仍是合理的术中血压控制选择。

局限性

  • 开放标签设计,但终点评估采用盲法。
  • 术中两组平均血压水平和血压变异性无显著差异,可能影响对干预效果的解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Current recommended blood pressure (BP) targets during mechanical thrombectomy (MT) rely on a one-size-fits-all approach aiming at preventing hypertension. The efficacy and safety of an individualized BP control during thrombectomy for ischemic stroke has not been well studied. We aimed to evaluate whether an individualized BP control during MT could improve functional outcome at 90 days. METHODS: We conducted a multicenter, open-label, blinded-endpoint, randomized clinical trial at 8 academic comprehensive stroke centers in France. Adult patients with an acute ischemic stroke due to an anterior large vessel occlusion and an indication for MT were eligible. Recruitment was performed between March 10, 2021, and September 18, 2023. Patients were randomly assigned (1:1) to an individualized BP group during MT (where the mean arterial pressure [MAP] was maintained within 10% of the first MAP measured before MT) or a control BP group (systolic BP maintained within 140 and 180 mm Hg). The primary outcome was favorable functional outcome, defined as a modified Rankin Scale score between 0 and 2 at 90 days. Safety outcomes included symptomatic intracranial hemorrhages at 24 hours and mortality at 90 days. RESULTS: Overall, 433 patients (median age, 69.3 years, 228 females [52.8%]) were assigned to an individualized BP group (n = 215) or the control BP group (n = 218); one was excluded because of consent withdrawal. No significant differences in mean BP levels or BP variability were observed between groups during the procedure. Favorable functional outcome at 90 days was observed in 94 patients (44.2%) in the individualized BP group and 106 patients (48.8%) in the control group (adjusted odds ratio, 0.82; 95% CI 0.54-1.24; p = 0.34). Mortality from any cause at 90 days was not significantly different between groups (18.8% in the individualized BP group vs 16.4% in the control BP group: adjusted odds ratio, 1.19; 95% CI 0.70-2.03). Rates of symptomatic intracranial hemorrhages were not different between the 2 groups. DISCUSSION: In patients with acute ischemic stroke due to an anterior large vessel occlusion, an individualized BP management during MT did not increase rates of favorable functional outcome at 90 days compared with a standard BP management. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, DETERMINE, number NCT04352296. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients undergoing mechanical thrombectomy for stroke due to anterior large vessel occlusion, functional outcomes at 90 days were similar with individualized BP management and standard BP management.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Maïer B, Gory B, Chabanne R, et al. Individualized vs Standard Blood Pressure Control During Thrombectomy for Ischemic Stroke: The DETERMINE Randomized Clinical Trial. Neurology. 2026. PMID: 42585603. doi:10.1212/WNL.0000000000218420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。